Aldeyra Therapeutics (ALDX) Cash from Operations (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Cash from Operations came in at 5110089.0 in Q1 2026, up 59.02% YoY from 3213489.27 in Q1 2025, and up 3.57% on a QoQ basis from 5299345.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Cash from Operations (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Cash from Operations data on file, last reported at 5110089.0 in Q1 2026.
- Quarterly Cash from Operations rose 59.02% year-over-year to 5110089.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25986072.0 (up 43.14% YoY) and the FY2025 annual result came in at 33345682.0, up 22.83% from the prior year.
- Cash from Operations improved to 5110089.0 in Q1 2026, from 5299345.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 500440.0 in Q4 2023 to a low of 19958593.0 in Q2 2022.
- A 5-year average of 9919284.29 and a median of 9972687.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 104.46% — and 2024, when it plunged 2505.25%.
- Tracing ALDX's Cash from Operations over 5 years: stood at 11231177.0 in 2022, then surged by 104.46% to 500440.0 in 2023, then sank by 2505.25% to 12036845.0 in 2024, then surged by 55.97% to 5299345.0 in 2025, then increased by 3.57% to 5110089.0 in 2026.
- The last three Cash from Operations figures came in at 5110089.0 (Q1 2026), 5299345.0 (Q4 2025), and 7021416.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | -4.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.59 Mn |
| Jun 30, 2026 | -4.59 Mn |
| Mar 31, 2026 | -5.11 Mn |
| Mar 31, 2026 | -5.11 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Jun 30, 2025 | -8.56 Mn |
| Jun 30, 2025 | -8.56 Mn |
| Mar 31, 2025 | -12.47 Mn |
| Mar 31, 2025 | -12.47 Mn |
| Dec 31, 2024 | -12.04 Mn |
| Dec 31, 2024 | -12.04 Mn |
| Sep 30, 2024 | -7.97 Mn |
| Sep 30, 2024 | -7.97 Mn |
| Jun 30, 2024 | -13.22 Mn |
| Jun 30, 2024 | -13.22 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Mar 31, 2024 | -9.97 Mn |